Abstract
We have investigated the effects of combination therapy with thymosin α1 and natural human lymphoblastoid interferon-α in human immunodeficiency virus infection and have shown that in vitro this combination treatment: (1) synergistically stimulated the cytotoxic activity against natural killer-sensitive target cells of lymphocytes collected from human immunodeficiency virus-infected donors and (2) did not interfere with the antiviral activity of zidovudine. We thus studied the effects of combination therapy with thymosin α1, interferon-α and zidovudine in patients with CD4+ lymphocytes ranging from 200 to 500/mm3 in a randomized non-blinded study and found that the treatment was well tolerated after 12 months of therapy and was associated with a substantial increase in the number and function of CD4+T cells. A similar effect was not observed in human immunodeficiency virus patients treated with zidovudine alone or associated with single agents. These data suggest the need for a controlled, double-blind clinical trial, recently initiated with the approval and the support of the Italian Ministry of Health.
| Original language | English |
|---|---|
| Pages (from-to) | 23-28 |
| Number of pages | 6 |
| Journal | International Journal of Clinical & Laboratory Research |
| Volume | 24 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1994 |
Fingerprint
Keywords
- Combination therapy
- Human immunodeficiency virus infection
- Interferon-α
- Thymosin α
- Zidovudine
ASJC Scopus subject areas
- Clinical Biochemistry
Cite this
Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infectionand interferon-α in human immunodeficiency virus infection. / Garaci, Enrico; Rocchi, Giovanni; Perroni, Luigi; D'Agostini, Cartesio; Soscia, Fabrizio; Grelli, Sandro; Mastino, Antonio; Favalli, Cartesio.
In: International Journal of Clinical & Laboratory Research, Vol. 24, No. 1, 01.1994, p. 23-28.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infectionand interferon-α in human immunodeficiency virus infection
AU - Garaci, Enrico
AU - Rocchi, Giovanni
AU - Perroni, Luigi
AU - D'Agostini, Cartesio
AU - Soscia, Fabrizio
AU - Grelli, Sandro
AU - Mastino, Antonio
AU - Favalli, Cartesio
PY - 1994/1
Y1 - 1994/1
N2 - We have investigated the effects of combination therapy with thymosin α1 and natural human lymphoblastoid interferon-α in human immunodeficiency virus infection and have shown that in vitro this combination treatment: (1) synergistically stimulated the cytotoxic activity against natural killer-sensitive target cells of lymphocytes collected from human immunodeficiency virus-infected donors and (2) did not interfere with the antiviral activity of zidovudine. We thus studied the effects of combination therapy with thymosin α1, interferon-α and zidovudine in patients with CD4+ lymphocytes ranging from 200 to 500/mm3 in a randomized non-blinded study and found that the treatment was well tolerated after 12 months of therapy and was associated with a substantial increase in the number and function of CD4+T cells. A similar effect was not observed in human immunodeficiency virus patients treated with zidovudine alone or associated with single agents. These data suggest the need for a controlled, double-blind clinical trial, recently initiated with the approval and the support of the Italian Ministry of Health.
AB - We have investigated the effects of combination therapy with thymosin α1 and natural human lymphoblastoid interferon-α in human immunodeficiency virus infection and have shown that in vitro this combination treatment: (1) synergistically stimulated the cytotoxic activity against natural killer-sensitive target cells of lymphocytes collected from human immunodeficiency virus-infected donors and (2) did not interfere with the antiviral activity of zidovudine. We thus studied the effects of combination therapy with thymosin α1, interferon-α and zidovudine in patients with CD4+ lymphocytes ranging from 200 to 500/mm3 in a randomized non-blinded study and found that the treatment was well tolerated after 12 months of therapy and was associated with a substantial increase in the number and function of CD4+T cells. A similar effect was not observed in human immunodeficiency virus patients treated with zidovudine alone or associated with single agents. These data suggest the need for a controlled, double-blind clinical trial, recently initiated with the approval and the support of the Italian Ministry of Health.
KW - Combination therapy
KW - Human immunodeficiency virus infection
KW - Interferon-α
KW - Thymosin α
KW - Zidovudine
UR - http://www.scopus.com/inward/record.url?scp=0028249186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028249186&partnerID=8YFLogxK
U2 - 10.1007/BF02592405
DO - 10.1007/BF02592405
M3 - Article
VL - 24
SP - 23
EP - 28
JO - Ricerca in Clinica e in Laboratorio
JF - Ricerca in Clinica e in Laboratorio
SN - 0940-5437
IS - 1
ER -